Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Celularity Inc. (NASDAQ: CELU)*

Organization & Developments: Celularity

Parents

2021: Celularity: Celgene Spin-Off Developing Allogeneic Therapies
2023: Celularity Warns of Potential Layoffs in Strategic Review_
Celularity believes that by harnessing the placenta's unique biology and ready availability, it will be able to develop therapeutic solutions that address a significant unmet global need for effective, accessible, and affordable therapeutics
Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placenta-derived allogeneic cell therapies, including genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and adherent stromal cells (ASCs), targeting indications across cancer infectious and degenerative diseases.